Lexicon Pharmaceuticals: all 61 studies

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of LX9211 in Participants With Postherpetic NeuralgiaCompletedNCT04662281Phase 2Results posted
• Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic PainCompletedNCT04455633Phase 2Results posted
• Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)TerminatedNCT03521934Phase 3Results posted
• Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlTerminatedNCT03386344Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminCompletedNCT03351478Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyCompletedNCT03332771Phase 3Results posted
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskTerminatedNCT03315143Phase 3Results posted
• Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart FailureTerminatedNCT03292653Phase 2Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic AgentsCompletedNCT03285594Phase 3Results posted
• Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlCompletedNCT03242252Phase 3Results posted
• A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlCompletedNCT03242018Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With MetforminCompletedNCT03066830Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of MetforminCompletedNCT02926950Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic TherapyCompletedNCT02926937Phase 3Results posted
• A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy AloneCompletedNCT02531035Phase 3Results posted
• Dose-ranging Study in Patients With Type 1 Diabetes MellitusCompletedNCT02459899Phase 2Results posted
• Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCompletedNCT02421510Phase 3Results posted
• Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCompletedNCT02384941Phase 3Results posted
• Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1CCompletedNCT02383940Phase 2Results posted
• Telotristat Etiprate for Carcinoid Syndrome TherapyCompletedNCT02063659Phase 3Results posted
• Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome SymptomsCompletedNCT02026063Phase 3Results posted
• Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusCompletedNCT01742208Phase 2Results posted
• TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)CompletedNCT01677910Phase 3Results posted
• A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative ColitisCompletedNCT01456052Phase 2Results posted
• Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on MetforminCompletedNCT01376557Phase 2Results posted
• Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid SyndromeCompletedNCT01104415Phase 2Results posted
• Study of LX4211 in Subjects With Type 2 Diabetes MellitusCompletedNCT00962065Phase 2Results posted
• Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable MethotrexateCompletedNCT00903383Phase 2Results posted
• Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide TherapyCompletedNCT00853047Phase 2Results posted
• Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid ArthritisCompletedNCT00847886Phase 1Results posted
• Study of LX1031 in Subjects With Non-Constipating Irritable Bowel SyndromeCompletedNCT00813098Phase 2Results posted
• Study of LX6171 in Elderly Volunteers With Age Associated Memory ImpairmentCompletedNCT00691808Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyActive, not recruitingNCT06481891Phase 3
• A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)CompletedNCT06203002Phase 2
• Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic ImpairmentCompletedNCT03423446Phase 1
• A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy SubjectsCompletedNCT03302845Phase 1
• Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal FunctionCompletedNCT02647918Phase 1
• Oral Contraceptive DDI StudyStatus unknownNCT02494609Phase 1
• PK Study of Sotagliflozin in Subjects With Hepatic ImpairmentCompletedNCT02471274Phase 1
• Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 TabletsCompletedNCT02373046Phase 1
• DDI Study With Multiple-dose LX4211 and Single Dose RosuvastatinCompletedNCT02300363Phase 1
• DDI Study With Multiple-dose LX4211 and Single Dose DigoxinCompletedNCT02300350Phase 1
• Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy SubjectsCompletedNCT02195635Phase 1
• An Open-Label Food Effect Study of Telotristat EtiprateCompletedNCT02157584Phase 1
• An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy SubjectsCompletedNCT02157558Phase 1
• A Thorough QT Study of Telotristat EtiprateCompletedNCT02155205Phase 1
• A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy SubjectsCompletedNCT02147808Phase 1
• An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in MalesCompletedNCT01932528Phase 1
• Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult SubjectsCompletedNCT01916863Phase 1
• Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy SubjectsCompletedNCT01916850Phase 1
• Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy SubjectsCompletedNCT01913002Phase 1
• Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male SubjectsCompletedNCT01818232Phase 1
• Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal ImpairmentCompletedNCT01555008Phase 1
• Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT01528111Phase 1/2
• A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel SyndromeCompletedNCT01494233Phase 2
• A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 DiabeticsCompletedNCT01441232Phase 1
• A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid ArthritisCompletedNCT01417052Phase 1
• An Open-Label Study of Two Formulations of LX1033 in Healthy Human SubjectsCompletedNCT01411800Phase 1
• A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy SubjectsCompletedNCT01334242Phase 1
• A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy SubjectsCompletedNCT01292993Phase 1
• Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes MellitusCompletedNCT01188863Phase 1

← Lexicon Pharmaceuticals overview and focus areas